Journal articles: 'Host vs Graft Reaction'

1

Goltz, Robert W. "The Graft-vs-Host Reaction." Archives of Dermatology 124, no. 12 (1988): 1849. http://dx.doi.org/10.1001/archderm.1988.01670120065012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Friedman, Kenneth J. "Acute Follicular Graft-vs-Host Reaction." Archives of Dermatology 124, no. 5 (1988): 688. http://dx.doi.org/10.1001/archderm.1988.01670050032014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Murphy, William J., Michael Bennett, Miriam R. Anver, Michael Baseler, and Dan L. Longo. "Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reactions." European Journal of Immunology 22, no. 6 (1992): 1421–27. http://dx.doi.org/10.1002/eji.1830220614.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Vashisht, Deepak, Rohit Kothari, Sukriti Baveja, Shekhar Neema, Prashant Sengupta, and Sunmeet Sandhu. "Follicular graft Vs host reaction: A rare presentation." Indian Dermatology Online Journal 11, no. 6 (2020): 988. http://dx.doi.org/10.4103/idoj.idoj_87_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Jones, D. C., and N. T. Young. "Natural killer receptors and graft-vs.-host/ graft-vs.-leukaemia reactions." Vox Sanguinis 87, s2 (2004): 15–17. http://dx.doi.org/10.1111/j.1741-6892.2004.00446.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Waer, M., V. Palathumpat, H. Sobis, and M. Vandeputte. "Induction of transplantation tolerance in mice across major histocompatibility barrier by using allogeneic thymus transplantation and total lymphoid irradiation." Journal of Immunology 145, no. 2 (1990): 499–504. http://dx.doi.org/10.4049/jimmunol.145.2.499.

Full text

Abstract:

Abstract The use of allogeneic thymus transplantation as a means of inducing tolerance across MHC barriers was investigated in thymectomized, total lymphoid irradiated BALB/c mice. In 90% of the animals long term outgrowth of histologically normal C57BL thymus grafts was observed. None of the latter animals was chimeric. All thymus graft-bearing mice showed specific nonresponsiveness for C57BL MHC Ag in mixed lymphocyte reaction and cell-mediated lympholysis. Spleen cells of the C57BL thymus-bearing mice were unable to induce lethal graft-vs-host disease in neonatal (BALB/c X C57BL) F1 mice but provoked a vigorous graft-vs-host disease reaction in (BALB/c x C3H) F1 neonates. Tolerant mice permanently accepted C57BL heart and pancreas grafts, but all rejected C3H grafts. Induction of tolerance of BALB/c pre-T cells through allogeneic thymus graft and/or specific suppressor cells seems to be involved. The present model offers new opportunities to study thymocyte maturation in a fully allogeneic environment and may yield applications for clinical organ transplantation.

APA, Harvard, Vancouver, ISO, and other styles

7

Hill, Wolfgang, Karl Sotlar, Heinz Diem, Andreas Hausmann, and Hans Jochem Kolb. "Bone Marrow Reaction in Chronic Graft-Versus-Host Disease." Blood 112, no. 11 (2008): 1166. http://dx.doi.org/10.1182/blood.v112.11.1166.1166.

Full text

Abstract:

Abstract Hematopoiesis of the host is a primary target organ of the graft-versus-host reaction. However histological analyses of the bone marrow are rarely reported. Here we report histological changes in the bone marrow of patients (pts) with and without chronic graft-versus-host disease (cGvHD). Bone marrow biopsies were obtained between 101 days and 4623 days (median:419 days) after transplantation as part of a controlled prospective phase ll study of patients with osteopenia/osteoporosis after allogeneic hematopoietic stem cell transplantation (HCT). Previously we reported an increased density of microvessels using an antibody against v. Willebrand factor (vW) (Hill W. et al Blood110, abstract No 1963; 2007). Here we report additional immunohistological and immunocytological findings in marrow and blood. We analyzed the number of CD34+ and vW+ microvessels as well as CD8+ suppressor/cytotoxic T-cells/mm² (T-S) in sequential biopsies of pts with (n=9) or without (n=6) cGvHD after median 2 years apart. Biopsies of 3 pts without HCT and without lymphoma involvement served as controls. Simultaneously lymphocyte subpopulations were evaluated in peripheral blood samples of pts with (n=16) or without (n=8) cGvHD. The pts were divided in 5 groups: neither aGvHD nor cGvHD; no cGvHD but acute GvHD before entry; cGvHD limited; cGvHD extensive without immunosuppression; cGvHD extensive with immunosuppression. Results: In the first biopsies the content of CD34+, vW+ microvessels and T-S cells were significantly higher in pts with cGvHD (group 3–5) than in those without cGvHD (group 1–2) (21,3 vs 8,2 p=0,03; 22,0 vs 9,2 p=0,002 respectively 106,2 vs 32,1 p=0,04). In the second biopsies these parameters were also increased in cGvHD: CD34+ (18,3 vs 11,2 p=0,02), vW+ (17,3 vs 9,0 p=0,08) microvessels and T-S cells (63,2 vs 37,8 p=0,27). The increased density of CD34+ and vW+ microvessels correlated with the number of T-S cells (p=0,05). As compared to normal controls we observed a significantly higher content of vW+ microvessels in all groups of transplanted pts (16,9 vs 4,2 p=0,03). In pts with cGvHD (group 3–5) CD34+ and vW+ microvessels were further increased (p=0,02 respectively p=0,002). At the time of the first biopsy the absolute T-S cell content in peripheral blood was moderately increased in group 5 (1124/ul) and minimally increased in group 2 (993/ul) (normal 270 – 880), whereas the overall T cell (CD3) content was normal in all groups. The percentage of activated T-S (HLA-DR+) cells was increased in all groups of transplanted pts (61,8% vs normal =33%; p=0,05). After two years T-S cells content was reduced in pts under immunosuppressive therapy (group 5) (1415 vs 900/ul; p=0.000) but remained increased over the norm. In group 4 T-S cell content was increased over the norm (800 vs 920/ul; p=0,043). In conclusion, sequential immunohistology and immunocytology analyses on bone marrow biopsies and peripheral blood provide evidence for the existence of a chronic graft-versus-host reaction of the bone marrow in pts with cGvHD. This is characterized by an increased content of CD34+ and vW+ microvessels and an increased content of T-S cells at least initially. However this reaction does not lead to a generalized hematopoietic insufficiency.

APA, Harvard, Vancouver, ISO, and other styles

8

Friedman, K. J. "Acute follicular graft-vs-host reaction. A distinct clinicopathologic presentation." Archives of Dermatology 124, no. 5 (1988): 688–91. http://dx.doi.org/10.1001/archderm.124.5.688.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hakim, F. T., S. Payne, and G. M. Shearer. "Recovery of T cell populations after acute graft-vs-host reaction." Journal of Immunology 152, no. 1 (1994): 58–64. http://dx.doi.org/10.4049/jimmunol.152.1.58.

Full text

Abstract:

Abstract We previously have observed that T dependent immune functions were deficient for several months after induction of acute suppressive graft-vs-host-reaction (GVHR) by injection of parental C57BL/10 donor spleen cells into unirradiated (B10 x B10.BR) F, hosts. We therefore investigated whether new T cells matured after acute GVHR, and whether these were tolerant of host Ag. By 8 to 17 mo after GVHR, the frequencies of splenic CD4 and CD8 T cells were found to be comparable to age-matched untreated hosts, although the lymphoid organ size and hence the total number of T cells was significantly reduced. When GVHR was induced with a combination of C57BL/6 (Thy-1.2) mature lymphocytes and B6.PL (Thy-1.1) bone marrow stem cells, the mature donor Thy-1.2 T cells initially predominated during the acute GVHR. After several months, however, 75% of the CD4 and 50% of the CD8 T cell population was derived from donor Thy-1.1% pre-T cells that had matured in the host. Long term GVHR spleen cells were unresponsive to host Ag in CTL assays, but did not suppress anti-host CTL responses. Finally, host-reactive V beta 11 TCR expressing cells were found to be clonally deleted from splenic CD4 and CD8 populations, consistent with intrathymic negative selection. This evidence suggests that the post-GVHR thymus has the capacity to produce and negatively select phenotypically mature CD4 and CD8 T cells and that a failure to clonally delete self-reactive populations is not a contributing factor to the development of chronic GVHR in this system.

APA, Harvard, Vancouver, ISO, and other styles

10

Pals, S. T., M. Zijstra, T. Radaszkiewicz, et al. "Immunologic induction of malignant lymphoma: graft-vs-host reaction-induced B cell lymphomas contain integrations of predominantly ecotropic murine leukemia proviruses." Journal of Immunology 136, no. 1 (1986): 331–39. http://dx.doi.org/10.4049/jimmunol.136.1.331.

Full text

Abstract:

Abstract The induction of a graft-vs-host reaction in (BALB/c X A)F1 mice by i.v. injection with BALB/c lymphoid cells leads to a lymphoid hyperplasia that may progress to malignant lymphoma. In the present paper, the following aspects of graft-vs-host-reaction lymphomagenesis were studied: 1) the cellular requirements for the induction of lymphomas, 2) their cellular origin, and 3) the role of murine leukemia viruses. The development of graft-vs-host-reaction lymphomas was found to be mediated by donor T cells and to require the presence of histoincompatibility between donor and host. Histologically, the vast majority of these lymphomas were either of follicular center cell or of immunoblastic type, whereas immunoperoxidase studies showed that they were virtually all B cell derived. Most of the lymphomas were of host origin. In the DNA of approximately 80% of the lymphomas, integrated murine leukemia virus proviruses were detected. In the B cell lymphoma DNA, integrated ecotropic proviruses prevailed, but recombinant murine leukemia virus and/or deleted murine leukemia virus genomes were also detected in some tumor DNA.

APA, Harvard, Vancouver, ISO, and other styles

11

Houssaint, E., A. Torano, and J. Ivanyi. "Split tolerance induced by chick embryo thymic epithelium allografted to embryonic recipients." Journal of Immunology 136, no. 9 (1986): 3155–59. http://dx.doi.org/10.4049/jimmunol.136.9.3155.

Full text

Abstract:

Abstract To test the capacity of the epithelial component of the chick embryo thymus to induce tolerance to major histocompatibility complex (MHC) antigens, pre-colonized thymic rudiments were grafted into chick embryonic recipients. Semi-allogeneic or allogeneic transplantations were done between two lines of chickens histocompatible at the MHC locus. Approximately 10% of these thymic chimeras hatched and were studied 3 mo after hatching. Thymic grafts were not rejected by the allogeneic host. The tolerance of chimeric chickens to thymus donor MHC antigens was tested by using a skin graft rejection test and a graft-vs-host (GvH) assay. Chimeric chickens that received an MHC-incompatible thymic graft during the embryonic life tolerated skin graft with the MHC haplotype of the thymus donor. Nevertheless, the lymphocytes within the thymic graft, the host thymus, and the blood were tolerant to the host MHC antigens but were alloreactive in GvH reaction for the MHC antigens of the thymic graft type. These results suggest that the epithelial component of the thymus when taken before the starting of the colonization by hemopoietic precursors and grafted into an early chick embryonic host can induce a tolerance for the MHC determinants involved in allograft rejection but not in the GvH reaction.

APA, Harvard, Vancouver, ISO, and other styles

12

Bril, Herman, Robbert Benner, and J. Wayne Streilein. "Graft-Vs.-Host Reactions: Mechanisms and Contemporary Theories." CRC Critical Reviews in Clinical Laboratory Sciences 22, no. 1 (1985): 43–95. http://dx.doi.org/10.1080/10408368509176815.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Rees, Michael A., Andrew J. Butler, Hugh Davis, et al. "GRAFT VS. HOST REACTION GENERATED BY PORCINE LIVERS PERFUSED WITH HUMAN BLOOD." Transplantation 67, no. 7 (1999): S222. http://dx.doi.org/10.1097/00007890-199904150-00885.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Horn, Thomas D. "Lichen Planus—Like Histopathologic Characteristics in the Cutaneous Graft-vs-Host Reaction." Archives of Dermatology 133, no. 8 (1997): 961. http://dx.doi.org/10.1001/archderm.1997.03890440027003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Kupers, Rudolf C., Tobias Suiter, Ernst Gleichmann, and Noel R. Rose. "The induction of organ-specific antibodies during the graft-vs. -host reaction." European Journal of Immunology 18, no. 1 (1988): 161–66. http://dx.doi.org/10.1002/eji.1830180124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Joseph, L. J., T. Iwasaki, T. R. Malek, and G. M. Shearer. "Interleukin 2 receptor dysfunction in mice undergoing a graft-vs-host reaction." Journal of Immunology 135, no. 3 (1985): 1846–50. http://dx.doi.org/10.4049/jimmunol.135.3.1846.

Full text

Abstract:

Abstract Mice of the (C57BL/10 X B10.A)F1 combination were given a single i.v. inoculation of 3 to 4 X 10(7) B10.A spleen cells, which induces a graft-vs-host (GVH)-associated immune deficiency in F1 mice. Between 1 and 4 wk later, spleen cells from the F1 mice were tested for the expression of IL 2 receptors by flow microfluorometry, using the 7D4 rat monoclonal antibody directed against an epitope murine IL 2 receptor. A reduction in intensity of spleen cell staining with 7D4 was detected as early as 8 days after parental cell inoculation, and no IL 2 receptors were detected by 28 days after initiation of GVH. Furthermore, the loss of IL 2 receptors was correlated with abrogation of proliferative responses to concanavalin A and lipopolysaccharide, of IL 2 production, and of cytotoxic T lymphocyte responses. These observations may be relevant for our understanding of GVH reactions, of immune disorders associated with GVH, and possibly of primary and acquired immunodeficiencies in general.

APA, Harvard, Vancouver, ISO, and other styles

17

Johnson, Bryon D., Emily E. Becker, and Robert L. Truitt. "Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets." Biology of Blood and Marrow Transplantation 5, no. 3 (1999): 123–32. http://dx.doi.org/10.1053/bbmt.1999.v5.pm10392958.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Ishikawa, H., K. Saito, and E. Kubota. "Modulation of F1 cytotoxic potentials by graft-vs-host reaction. Cooperative non-H-2- and H-2D region-gene control of F1 natural resistance to graft-vs-host reaction-associated immunosuppression." Journal of Immunology 142, no. 5 (1989): 1495–99. http://dx.doi.org/10.4049/jimmunol.142.5.1495.

Full text

Abstract:

Abstract Our previous study revealed that in F1 mice raised by crossing C3H/He or AKR/J mice with various H-2-congenic B10-series strains, parental H-2k spleen cells (SC) could not induce the graft-vs-host reaction (GvHR)-associated immunosuppression (GAIS). We also elucidated that a limited number of non-H-2 genes of parental C3H/He or AKR/J mice that had been incorporated into the F1 hybrids determined the F1 resistance to the GAIS, and the present study was done to explore the mechanism implicated in this type of F1 resistance to GAIS. SC from B10.AL mice carrying an rH-2 (K:k I:k S:k D:d) haplotype but not SC from H-2K B10.BR (k k k k) mice induced GAIS of in vitro CTL responses to third-party alloantigens in H-2k/d (C3H/He x B10.D2)F1 recipients mice. Further, SC from H-2k/a (C3H/He x B10.A)F1 mice carrying heterozygous C3H/B10 non-H-2 background but not SC from the same H-2k/a (B10.BR x B10.A)F1 mice but carrying homozygous B10/B10 background induced GAIS in H-2k/d (C3H/He x B10.D2)F1 recipients. Although C3H/He-, B10.BR-, and C3H.OH (d d d k)-SC were incapable of inducing GAIS in (C3H/He x B10.D2)F1 (k/d k/d k/d k/d) recipients, they were all good inducers of GAIS in (C3H.OH x B10.BR)F1 (d/k d/k d/k k/k) recipients. Exactly the same pattern of co-operative non-H-2 AKR and H-2D region-gene control of GAIS was observed on GvHR induced in H-2k/d (AKR/J x B10.D2)F1 recipients. These results suggest that the non-H-2 genes of C3H/He or AKR/J strain inhibit the functional expression of certain antigenic determinant(s) when it is encoded by heterozygous but not homozygous gene(s) linked tightly to H-2D region of k haplotype. Thus, the F1 resistance to GAIS is mediated by immune response of F1 recipients who miss the antigenic determinant(s) against that expressed on cell surface of GvHR-inducing T lymphocytes.

APA, Harvard, Vancouver, ISO, and other styles

19

Goltz, R. W. "The graft-vs-host reaction. An iatrogenic model for a number of skin disorders." Archives of Dermatology 124, no. 12 (1988): 1849–50. http://dx.doi.org/10.1001/archderm.124.12.1849.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Bauer, Diane J. "Histologic Comparison of Autologous Graft-vs-Host Reaction and Cutaneous Eruption of Lymphocyte Recovery." Archives of Dermatology 129, no. 7 (1993): 855. http://dx.doi.org/10.1001/archderm.1993.01680280043007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Bauer, D. J. "Histologic comparison of autologous graft-vs-host reaction and cutaneous eruption of lymphocyte recovery." Archives of Dermatology 129, no. 7 (1993): 855–58. http://dx.doi.org/10.1001/archderm.129.7.855.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Chisholm, Patricia M., Mark T. Drayson, Josephine H. Cox, and William L. Ford. "The effects of cyclosporin on lymphocyte activation in a systemic graft-vs.-host reaction." European Journal of Immunology 15, no. 10 (1985): 1054–59. http://dx.doi.org/10.1002/eji.1830151018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Praloran, V., C. Raventos-Suarez, A. Bartocci, J. Lucas, E. R. Stanley, and J. J. Gibbons. "Alterations in the expression of colony-stimulating factor-1 and its receptor during an acute graft-vs-host reaction in mice." Journal of Immunology 145, no. 10 (1990): 3256–61. http://dx.doi.org/10.4049/jimmunol.145.10.3256.

Full text

Abstract:

Abstract During the course of an acute graft-vs-host reaction in the mouse we observed a progressive increase in the concentration of CSF-1 in serum and liver, peaking at day 14. In contrast, there was a progressive decrease in the splenic CSF-1 concentration. In vivo studies of 125I-CSF-1 uptake and degradation and in vitro studies of 125I-CSF-1 binding by splenic cells demonstrated that within 24 h of the reaction the number of CSF-1 receptor+ cells had increased by 2-fold and their capacity to express the CSF-1 receptor by approximately 3-fold, resulting in a approximately 2.5-fold increase in the splenic clearance of CSF-1 from the circulation. Inasmuch as at 24 h, serum CSF-1 was not significantly altered, these results are suggestive of an increased rate of release of CSF-1 into the circulation early in the response. The splenic CSF-1-receptor bearing cells were in a Mac-1+ fraction that is consistent with a role for CSF-1 in the generation of host-derived splenic macrophages in acute graft-vs-host reaction.

APA, Harvard, Vancouver, ISO, and other styles

24

Theofilopoulos, A. N., R. S. Balderas, Y. Gozes, et al. "Association of lpr gene with graft-vs.-host disease-like syndrome." Journal of Experimental Medicine 162, no. 1 (1985): 1–18. http://dx.doi.org/10.1084/jem.162.1.1.

Full text

Abstract:

Hemopoietic cells have been reciprocally transferred between two lines of mice (MRL lpr/lpr and MRL +/+) that are congenic, differing only at the lpr (lymphoproliferation) and possibly closely linked genes. The lpr strain develops a significantly more severe and fast-paced lupus-like syndrome than +/+ strain, along with a substantially larger lymphoid mass. The results showed that: (a) hemopoietic cells of such mice were sufficient to induce the respective disease phenotypes in lethally irradiated syngeneic recipients; (b) cells of MRL +/+ mice maturing in an MRL lpr/lpr environment essentially retained the disease-producing characteristics of the donor, i.e., they induced late-life lupus without lymphadenopathy; but (c) MRL lpr/lpr cells transferred into irradiated MRL +/+ recipients unexpectedly failed to induce the early-life severe lupus and lymphoid hyperplasia of the donor, instead they caused a severe wasting syndrome resembling, in many respects, graft-vs.-host disease (GVHD). This GVHD-like syndrome developed after transfer of MRL lpr/lpr fetal liver, bone marrow, or spleen cells, and was not abrogated by elimination of T cells from the inocula. Thymectomy of the MRL +/+ recipients retarded, but did not prevent, the wasting disease. The unidirectional nature of this disease suggests that the lpr mutation conferred either a structural or regulatory defect that interfered, blocked, or altered the expression or structure of certain lymphocyte antigen(s). As a result, the MRL +/+ cells that did express this antigen(s) were recognized as foreign, and stimulated a graft-vs.-host reaction. These findings may allow definition of a new kind of rejection phenomenon caused by non-H-2 products, and may extend our understanding of the means by which the lpr gene adversely affects lymphocyte regulation and homeostasis.

APA, Harvard, Vancouver, ISO, and other styles

25

Yu, Xue-Zhong, Sasha Bidwell, Paul J. Martin, and Claudio Anasetti. "Visualization, Fate, and Pathogenicity of Antigen-Specific CD8+ T Cells in the Graft-Versus-Host Reaction." Journal of Immunology 163, no. 9 (1999): 4780–87. http://dx.doi.org/10.4049/jimmunol.163.9.4780.

Full text

Abstract:

Abstract To follow the fate of alloreactive T cell effectors in graft-vs-host disease, Ld-specific CD8+ T cells from C57BL/6 2C TCR-transgenic donors were transplanted into sublethally irradiated (750 cGy) Ld+ or Ld− recipients. In Ld− C57BL/6 or (BALB/c-dm2 × C57BL/6)F1 recipients, naive 2C T cells engrafted and survived long term, but did not acquire effector function. In Ld+ (BALB/c × C57BL/6)F1 recipients, 2C T cells engrafted, expanded, became cytolytic, destroyed host B cells and double-positive thymocytes, and later disappeared. Despite marked damage to lymphoid and hemopoietic cells by 2C T cells, no significant pathology was detected in other organs, and recipients survived. Ld+ (BALB/c × C57BL/6)F1 recipients died when LPS/endotoxin was administered on day 7 after cell transfer, while Ld− (BALB/c-dm2 × C57BL/6)F1 recipients survived. Our findings show that under certain conditions, a CD8+ T cell population recognizing an extremely limited repertoire of Ags can initiate graft-vs-host disease.

APA, Harvard, Vancouver, ISO, and other styles

26

De Wit, D., M. Van Mechelen, C. Zanin, et al. "Preferential activation of Th2 cells in chronic graft-versus-host reaction." Journal of Immunology 150, no. 2 (1993): 361–66. http://dx.doi.org/10.4049/jimmunol.150.2.361.

Full text

Abstract:

Abstract The injection of DBA/2 parental lymphocytes into adult, immunologically intact (C57BL/6 x DBA/2) F1 hybrid mice results in a chronic graft-vs-host reaction (GVHR) characterized by a deficiency in CD4+ T cell functions and a B cell activation leading to autoantibody production. The discovery that distinct subpopulations of Th cells may regulate the effector immune functions led us to investigate whether the chronic GVHR differentially affects Th subsets. Data are presented indicating that mice undergoing a GVHR spontaneously produced lymphokines of Th2 origin. IL-4 and IL-10 mRNA were detected in the spleens of GVH mice, and IL-4 was shown to be responsible for the increased expression of class II Ag on B cells. Moreover, upon polyclonal activation in vitro, GVH T cells exhibited defective IL-2 and IFN-gamma production but elevated IL-4 production. We conclude that the chronic GVHR is characterized by a selective deficiency in cells secreting IL-2 and IFN-gamma and a hyperactivation of Th2 cells. The simultaneous production of IL-4 and IL-10 might explain the association between B cell hyperactivity and impairment of Th1-like activities in various models that associate autoimmunity and immunosuppression, such as GVHR and HIV infection.

APA, Harvard, Vancouver, ISO, and other styles

27

DE BONAPARTE, YOLANDA P., LUCAS L. COLOMBO, SLOBODANKA KLEIN, ISABEL S. D'ELIA, and MIRIAM DIAMENT. "Graft-vs-Host Reaction Induced by Para-aortic Lymph Nodes During Estrous and Diestrous Stages." American Journal of Reproductive Immunology and Microbiology 12, no. 2 (1986): 45–47. http://dx.doi.org/10.1111/j.1600-0897.1986.tb00061.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Du, Jing, Ryan P. Flynn, Katelyn Paz, et al. "Pirfenidone Reverses Murine Chronic Graft Versus Host Disease." Blood 128, no. 22 (2016): 1158. http://dx.doi.org/10.1182/blood.v128.22.1158.1158.

Full text

Abstract:

Abstract Allogeneic hematopoietic stem cell transplantation (aHSCT) is hampered by chronic graft-versus-host disease (cGVHD), which results in multi-organ fibrosis and loss of function. In particular, bronchiolitis obliterans (BO) and scleroderma resulting from fibrotic bronchiolar and cutaneous response, respectively, are two devastating outcomes for cGVHD patients. Fibrotic manifestations often are considered irreversible and progressive. Therefore, new therapies targeting fibrosis are urgently needed. Pirfenidone (5-methyl-1-phenyl-2- (1H)-pyridone) exhibits a well-documented anti-inflammatory and anti-fibrosis function in multiple pre-clinical models and is the first and only FDA-approved drug for idiopathic pulmonary fibrosis. For this study, Pirfenidone was synthesized as a crystalline solid and found to be pure both by melting point and NMR spectroscopy. We evaluated Pirfenidone's anti-fibrosis function in 2 pathophysiologically distinct cGVHD murine models: 1. a major mismatched multi-organ system model (C57BL/6 to B10.BR) that induces BO as a result of a cGVHD-induced germinal center (GC) reaction, antibody deposition and fibrosis in the lung; and 2. a minor antigen mismatched model (B10.D2 to BALB/c) in which severe scleroderma is the major disease manifestation. In the BO model, pulmonary function loss in cGVHD mice (as reflected by increased resistance, elastance and decreased compliance of the lung) was restored by Pirfenidone treatment (400mg/kg) during both the early (day28-56) (Fig A, representative of 3 experiments with 5-8 mice per group) and late stages (day56-84) of the disease. Pathologic changes in the lung, such as collagen deposition and narrowing of bronchioles, were significantly reduced by Pirfenidone. The size and frequency of GCs in the spleen, and the frequency of GC B cells (Fig B, representative of 2 experiments with 5-8 mice per group) and T follicular helper cells were all significantly reduced in Pirfenidone- treated groups. To determine whether GCs were directly affected by Pirfenidone, we evaluated Pirfenidone in C57BL/6 mice immunized with sheep red blood cells (SRBC) to induce GCs. Interestingly, Pirfenidone did not reduce the SRBC-induced GC reaction (Fig C) (comparable frequencies of splenic GC B cells, T follicular helper cells and serum IgG levels were seen between Pirfenidone and vehicle-treated groups). These results suggested that Pirfenidone suppresses the GC reaction through a cGVHD-specific mechanism, rather than through immune regulation. Mechanistically, Pirfenidone administration attenuated the sequestration of pro-fibrogenic F4/80+ macrophages (Fig D, representative of 2 experiments) and TGF-β (Fig E, representative of 2 experiments) production within the lung. These results have led us to elucidate a potential mechanism of cGVHD: antibody deposition in the lung results in the activation of macrophages and TGF-β that drive fibrotic change and tissue damage, resulting in the exposure of auto- and allo- antigens to the immune system that support and sustain pathologic GC reactions. In the B10.D2 to BALB/c sclerodermatous cGVHD model, Pirfenidone treatment (400mg/kg, day21-55) improved clinical signs of scleroderma and reduced macrophage infiltration in the skin (Fig F). In summary, this is the first study evaluating a commercially available anti-fibrosis drug on pathologically distinct pre-clinical cGVHD models. Our data suggests Prifenidone reversed cGVHD in the BO model and, to a lesser extent, in the scleroderma model. Thus, Pirfenidone is a novel therapeutic agent for treating cGVHD patients with fibrosis that have been typically refractory to therapies. A. Resistance of lungs was measured on day56 of transplantation; Elastance and compliance correlated with resistance but were not shown here. B. Flow cytometry analysis of GC B cells of no cGVHD vs cGVHD mice treated with Pirfenidone or vehicle; C. Flow cytometry analysis of GC B cells from SRBC-immunized mice treated with Pirfenidone or vehicle; D and E. Macrophage F4/80 and TGF-β quantification of day56 lungs of no cGVHD vs cGVHD mice treated as indicated; F. Skin GVHD scores were recorded on indicated dates of irradiated BALB/c mice transplanted with B10.D2 donor BM alone or with T cells and treated as indicated. Unpaired student T test was used for statistical analysis. ****:P<0.0001; ***: P<0.001; **: P<0.01; *: P<0.05; ns: not significant. Figure Figure. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

29

Fukuzawa, M., C. S. Via, and G. M. Shearer. "Defective thymic education of L3T4+ T helper cell function in graft-vs-host mice." Journal of Immunology 141, no. 2 (1988): 430–39. http://dx.doi.org/10.4049/jimmunol.141.2.430.

Full text

Abstract:

Abstract Our study investigates the effect of a prior graft-vs-host (GVH) reaction on the subsequent ability of irradiated, bone marrow-re-populated mice to develop T cell function. The results indicate that such GVH-bone marrow transplanted (BMT) mice do not generate CTL responses to trinitrophenyl-modified syngeneic cells (TNP-self), but do generate strong CTL activity to H-2 alloantigens. This selective deficiency in TNP-self CTL response potential appeared as early as 10 days after GVH, and required both L3T4+ and Lyt-2+ donor T cells. The in vitro addition of either soluble Th factors or L3T4-enriched spleen cells from normal mice circumvented the defect in the TNP-self response in GVH-BMT mice. These results indicate that T effector function was not defective, and instead suggest a Th defect. Cell depletion and antibody-blocking, as well as IL-2 production experiments, indicate that the Th defect was selective for L3T4+ Th population and not for Lyt-2+ Th population. This defect in L3T4 Th function is not accounted for by the approximate twofold reduction in L3T4 cell numbers in GVH-BMT mice, because IL-2 production and CTL generation to L3T4-dependent Ag were at least eightfold below control levels. Rather, defective L3T4 Th function appears to be the consequence of a GVH-induced defect in thymic maturation because the defect was corrected in vivo by a neonatal parental thymus graft before irradiation and bone marrow transplantation. This system may be useful for elucidating the role of the thymus in the maturation of Th cells. Our findings raise the possibility that impaired development of T cell function occurring in marrow grafted patients who have undergone a GVH reaction could be partly due to a GVH-induced thymic defect.

APA, Harvard, Vancouver, ISO, and other styles

30

Pelot, Michele R., Denise A. Pearson, Kirsten Swenson, et al. "Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen." Biology of Blood and Marrow Transplantation 5, no. 3 (1999): 133–43. http://dx.doi.org/10.1053/bbmt.1999.v5.pm10392959.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Le Deist, F., C. Raffoux, C. Griscelli, and A. Fischer. "Graft vs graft reaction resulting in the elimination of maternal cells in a SCID patient with maternofetal GVHd after an HLA identical bone marrow transplantation." Journal of Immunology 138, no. 2 (1987): 423–27. http://dx.doi.org/10.4049/jimmunol.138.2.423.

Full text

Abstract:

Abstract In a young girl with a severe combined immunodeficiency, the presence of circulating maternal T lymphocytes was proven by HLA typing. Manifestations of skin graft vs host disease were associated with the persistence of maternal cells. The patient received an HLA identical bone marrow transplantation from her brother without any conditioning. The bone marrow transplantation was quickly followed by a transient and dramatic increase in skin lesions associated with fever and the finding of a high number of circulating lymphocytes and eosinophils. Lymphocytes were shown to be of donor origin and exerted a spontaneous cytotoxic activity toward maternal cells. This activity progressively disappeared within 90 days, whereas maternal cells were no longer detected in patient's blood, and skin graft vs host disease was resolved within 8 wk. Cytotoxic activity was proven to be mediated by donor T lymphocytes specific for the mother's HLA antigens. The cytotoxic activity was demonstrated to be specific for the HLA class I molecules of the mother not shared with her daughter (HLA A1, B17) as shown by the use of a series of HLA typed cells as targets. In addition, cold K562 target cells did not block the cytotoxic activity, and the kinetics of the cytotoxic activity did not correlate with that of natural killer activity emergence after the bone marrow transplantation. Patient's serum did not contain antibodies toward maternal specific HLA class I antigen. Cytotoxic activity was totally blocked by anti-T3 monoclonal antibodies and partially by anti-T8 and anti-T4. It is thus likely that donor origin cytotoxic T lymphocytes were promptly activated after bone marrow transplantation and provoked the elimination of the maternal graft after a transient exacerbation of graft vs host disease manifestations. This observation represents one of the first examples of the possible role in vivo of allogeneic cytotoxic lymphocytes in humans.

APA, Harvard, Vancouver, ISO, and other styles

32

Pereira, Andre Domingues, Vinicius Campos de Molla, Ana Rita Da Fonseca, et al. "Ikaros Expression in the Graft Is Associated with Chronic Graft Versus Host Disease." Blood 136, Supplement 1 (2020): 1–2. http://dx.doi.org/10.1182/blood-2020-138981.

Full text

Abstract:

Introduction: Hematopoietic stem cell transplantation (HSCT) is the only potentially curative treatment for several diseases. Immune reconstitution post HSCT is a complex and extremely variable process. Ikaros transcription factor has an important role in hematopoiesis of several cell lines, especially in the lymphoid compartment. We hypothesized that Ikaros expression, both in the graft and in the recipient after transplant, might influence immune reconstitution and, consequently, the risk of opportunistic infections, relapse, and graft versus host disease (GVHD). Objectives: To correlate Ikaros expression both in the graft and in the recipient's peripheral blood (PB) after engraftment with the risk of GVHD after allogeneic HSCT outcomes. Patients and methods: 51 patients were included. Median age was 51 years (19-80), 53% of patients were male, and 57% of them had acute leukemia. Donor were haploidentical in 45% of cases, related identical in 29% and unrelated identical in 26%. Most patients (82%) received reduced-intensity conditioning regimens. Median follow-up was 20 months (10-40 months). Samples were collected from the graft and from the PB of the recipient 3 weeks after neutrophil recovery. Real time polymerase chain reaction (RT-PCR) was performed for analysis of absolute and relative Ikaros expression. Results: There was no association between Ikaros expression and the risk of acute GVHD, relapse or mortality. However, a significant association was observed in the risk of chronic GVHD. Cumulative incidence (CI) of chronic GVHD and of moderate / severe chronic GVHD (according to National Institute of Health - NIH classification) in two years were 49% and 28%, respectively. Higher Ikaros expression in the graft was associated with a significantly higher risk of moderate/severe chronic GVHD (54% vs. 15%, respectively, P=0.01). Higher Ikaros expression in the recipient's PB after engraftment was also associated with a significantly higher risk of moderate/severe chronic GVHD (65% vs. 11%, respectively, P=0.01). Conclusions: Ikaros expression in the graft and in the PB of the recipient after transplant seems to be correlated with a higher risk of moderate/severe chronic GVHD and might be evaluated in larger and prospective trials as a potential biomarker. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

33

Feuerstein, Nili, Fangqi Chen, Michael Madaio, Michael Maldonado, and Robert A. Eisenberg. "Induction of Autoimmunity in a Transgenic Model of B Cell Receptor Peripheral Tolerance: Changes in Coreceptors and B Cell Receptor-Induced Tyrosine-Phosphoproteins." Journal of Immunology 163, no. 10 (1999): 5287–97. http://dx.doi.org/10.4049/jimmunol.163.10.5287.

Full text

Abstract:

Abstract Abrogation of peripheral tolerance in transgenic mice that express a uniform B-cell receptor may create a powerful tool to examine the molecular mechanisms that underlie the autoimmune response in B cells. Here we report that processes that induce a systemic lupus erythematosus-like syndrome in normal mice, namely chronic graft vs host reaction, trigger systemic autoimmunity in a well-established transgenic mice model of B cell receptor peripheral tolerance. The induction of graft vs host reaction in mice that carry both a rearranged B cell Ag receptors specific for hen egg lysozyme and expressing chronically circulating hen egg lysozyme Ag resulted in induction of high and sustained levels of circulating anti-hen egg lysoyme autoantibodies and glomerulonephritis with proteinuria. This was associated with marked changes in expression of cell-surface proteins, such as CD23 and complement receptor 2. B cells from the graft vs host-induced mice could proliferate in vitro in response to self-Ag, and upon stimulation with anti-IgD demonstrated rapid phosphotyrosine phosphorylation of specific proteins, which could not be induced in the anergic double transgenic B cells. Conversely, loss of tolerance was not associated with a higher induction in the level of Syk kinase phosphorylation following stimulation with anti-IgD. Taken collectively, these data establish that 1) processes that induce a systemic lupus erythematosus-like syndrome in normal mice can abrogate peripheral tolerance in transgenic mice expressing self-tolerized B cells, and that 2) loss of tolerance in this model is associated with marked changes in surface expression of B cell coreceptors as well as with selective changes in IgD-induced signaling by discrete tyrosine-phosphoproteins, but not Syk kinase.

APA, Harvard, Vancouver, ISO, and other styles

34

Rieker, Theresa, Josef Penninger, Karel Hala, Max D. Cooper, and Georg Wick. "In situ analyses of in ovo graft-vs.-host reaction induced by thymic nurse cell lymphocytes." European Journal of Immunology 23, no. 4 (1993): 904–10. http://dx.doi.org/10.1002/eji.1830230421.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Huchet, R., M. Bruley-Rosset, C. Mathiot, D. Grandjon, and O. Halle-Pannenko. "Involvement of IFN-gamma and transforming growth factor-beta in graft-vs-host reaction-associated immunosuppression." Journal of Immunology 150, no. 6 (1993): 2517–24. http://dx.doi.org/10.4049/jimmunol.150.6.2517.

Full text

Abstract:

Abstract The mechanisms of the suppressive activity of spleen cells from mice undergoing a graft-vs-host reaction (GVH) to non-H-2 histocompatibility Ag were investigated. In our model GVH is induced by injecting bone marrow and spleen cells from B10.D2 (H-2d Mlsb) donors into lethally irradiated (DBA/2 x B10.D2)F1 (H-2d/d Mlsa/b) recipients that differ only with regard to non-H-2 Ag. GVH spleen cells inhibit the mitogenic responses to Con A and LPS, as well as the anti-bromelain-treated mouse RBC (Br-MRBC) antibody response. This suppression was nonspecific and non-H-2-restricted and was not modified after treatment with anti-Thy-1 plus C. Conversely it was abrogated after treatment with L-leucyl methyl ester. These features permitted the identification of non-T cell, L-leucyl methyl ester-sensitive, cells involved in this type of suppression. The suppression mediated by GVH spleen cells was linked to the activity of IFN-gamma and transforming growth factor-beta 1 (TGF-beta 1) (TGF-beta 1 was found to be synthesized by GVH spleen T cells). mAb to IFN-gamma abrogated the suppression of the mitogenic response to Con A and the anti-Br-MRBC response and slightly reversed the suppression of the mitogenic response to LPS. Anti-TGF-beta 1 antibody partially abrogated the suppression of the mitogenic response to LPS and totally abrogated that of the anti-Br-MRBC response but left unmodified the suppression of the mitogenic response to Con A. These results are discussed within the framework of the mechanisms underlying the immunosuppression associated with GVH.

APA, Harvard, Vancouver, ISO, and other styles

36

Pals, S. T., T. Radaszkiewicz, L. Roozendaal, and E. Gleichmann. "Chronic progressive polyarthritis and other symptoms of collagen vascular disease induced by graft-vs-host reaction." Journal of Immunology 134, no. 3 (1985): 1475–82. http://dx.doi.org/10.4049/jimmunol.134.3.1475.

Full text

Abstract:

Abstract The induction of a GVHR in (BALB/c X A)F1 mice by i.v. injection of 80 to 120 X 10(6) BALB/c spleen cells leads to the development of chronic progressive polyarthritis, which shares several of the articular and extra-articular manifestations of human rheumatoid arthritis. The development of these lesions was found to be mediated by donor T cells and to require the presence of histoincompatibility between donor and host. The arthritis, which was mainly confined to the interphalangeal joints of the forefeet and hindfeet, was histologically characterized by periarticular and synovial lymphoid infiltrations, as well as synovial proliferation and pannus formation. Prominent juxta-articular lesions included 1) perivascular infiltrates, 2) peritendinitis, 3) myositis, and 4) inflammatory nodules. In addition, the GVH F1 mice showed pathologic symptoms reminiscent of other collagen vascular diseases, including the following: 1) a Sjögren-like salivary gland lesion, 2) lesions resembling sclerosing cholangitis, 3) scleroderma-like skin lesion, and 4) immune-complex glomerulonephritis. In most of the GVH F1 mice, these pathologic changes were accompanied by lymphoid stimulation. The spectrum of symptoms induced has many similarities to that found in mixed connective tissue disease.

APA, Harvard, Vancouver, ISO, and other styles

37

Maeda, Yoshinobu, Pavan Reddy, Chen Liu, D. Keith Bishop та James L. M. Ferrara. "Host γd T cells Exacerbate Experimental Acute Graft-Versus-Host Disease through Activation of Host Antigen Presenting Cells." Blood 104, № 11 (2004): 3045. http://dx.doi.org/10.1182/blood.v104.11.3045.3045.

Full text

Abstract:

Abstract Large numbers of T cells bearing γd T cell receptors are present in graft-versus-host disease (GVHD) target tissues. We investigated the potential role of host γd T cells during acute GVHD in a well-characterized GVHD model following full intensity conditioning (11 Gy TBI). BM and spleen T cells from BALB/c (H2d) donors were transplanted into wild type (wt) B6, aß T cell deficient B6 (aß −/−) or γd T cell deficient B6 (γd −/−) hosts. γd −/− hosts demonstrated significantly better day 35 survival (85%) than wt (40%) or aß−/− hosts (18%) (P&lt;0.05). Reconstitution of γd −/− B6 hosts with B6 type γd T cells 24 hr prior to BMT restored lethal GVHD (50 % day 35 survival). In vivo, γd −/− B6 hosts demonstrated at least a five fold reduction in donor T cell expansion and cytokine production. In vitro, T cells proliferated less when co-cultured with allogeneic γd −/− dendritic cells (DCs) than with wt DCs (40,127 ± 1634 vs. 72,503 ± 1296, P&lt;0.05). BM-derived DCs cultured with γd T cells caused greater proliferation of allogeneic T cells than DCs cultured with aß T cells (15.1 ± 21 x 104 vs. 5.1 ± 1.2 x 104, P&lt;0.05). We next tested the effect of γd T cells on host DCs in vivo using a model system in which only the DCs injected prior to BMT expressed the alloantigen that stimulated the GVHD reaction. MHC Class II −/− B6 mice that had been depleted of γd T cells were given 11 Gy TBI and injected one day prior to BMT with B6 DCs that had been co-cultured either with γd T cells or with medium. On day 0 both groups of recipient mice were injected with BM plus splenic T cells from allogeneic bm12 donors. On day +5, CD4+ donor T cells expanded four times more in recipients of DCs co-cultured with γd T cells than in recipients of control DCs and serum levels of TNF-a were significantly higher (36.7 + 6.8 vs. 21.3 + 3.7 pg/ml, P&lt;0.05). Together these data demonstrate that γd T cells amplify the stimulatory function of host DCs and increase the severity of GVHD, suggesting that a new therapeutic target for the prevention of the major BMT toxicity.

APA, Harvard, Vancouver, ISO, and other styles

38

Ellison, Cynthia A., Jacqie M. M. Fischer, Kent T. HayGlass та John G. Gartner. "Murine Graft-Versus-Host Disease in an F1-Hybrid Model Using IFN-γ Gene Knockout Donors". Journal of Immunology 161, № 2 (1998): 631–40. http://dx.doi.org/10.4049/jimmunol.161.2.631.

Full text

Abstract:

Abstract These experiments were performed to determine whether the absence of donor-derived IFN-γ would influence the outcome of acute graft-vs-host disease (GVHD). Graft-vs-host reactions were induced in B6D2F1 hybrids using grafts from either IFN-γ gene knockout (gko) or wild-type, C57BL/6J, parental strain donors. GVHD was equally lethal in both groups, but IFN-γ gko graft recipients developed a more protracted form of the disease. These mice developed early wasting that persisted until death. IFN-γ was present in spleen cell cultures from wild-type graft recipients, but was absent in cultures from IFN-γ gko graft recipients. Both recipient groups showed macrophage priming for LPS-induced TNF-α release. Engraftment of donor-derived CD4+ and CD8+ cells was greater in IFN-γ gko graft recipients. Pathologic changes in IFN-γ gko graft recipients were different from those typically seen in acute GVHD. The syndrome developing in IFN-γ gko recipients consisted of patchy alopecia, corneal dryness and clouding, and lymphocytic infiltration of the liver, pancreas, salivary gland, lung, and kidney. Lymphocytic infiltrates were also present in the epidermis and the epithelium of both bile and salivary gland ducts. Some of the lesions closely resembled those seen in the “sicca”/Sjogren’s-like syndrome associated with chronic GVHD; however, there was no evidence of immune complex deposition in the kidney. These results indicate that GVHD in IFN-γ gko graft recipients shares many features with acute GVHD, but both the duration of the disease and its pathologic manifestations are different. Our results suggest that IFN-γ plays a significant role in the pathogenesis of acute GVHD by increasing the rate at which mortality develops.

APA, Harvard, Vancouver, ISO, and other styles

39

Lang, P., M. Dardenne, W. Savino, S. Moritz, and G. Shearer. "Cytotoxic T cell response and thymic hormonal dysfunction in graft-vs-host mice." Journal of Immunology 136, no. 6 (1986): 1999–2004. http://dx.doi.org/10.4049/jimmunol.136.6.1999.

Full text

Abstract:

Abstract As an approach to dissect complex mechanisms that lead to graft-vs-host (GvH)-associated immune disorders, we have compared the splenic cytotoxic T lymphocyte (CTL) response and thymic hormonal function in nonirradiated F1 hybrid mice injected with parental spleen cells. Thymic secretory function was studied by the determination of serum thymulin levels, and the number of thymic epithelial cells containing thymulin as assessed by indirect immunofluorescence with the use of an anti-thymulin monoclonal antibody. In addition, the epithelial cell network was analyzed with an anti-keratin serum, and the general histology pattern was studied by conventional histologic methods. An initial analysis was performed on day 15, which was characterized by CTL suppression mediated by parental suppressor T cells. No thymic abnormalities were detected at this time. By day 45 after GvH induction, active CTL suppression had decreased, and GvH was associated with a progressive decline in thymic hormonal function. Finally, by day 60 and thereafter, F1 GvH mice recovered normal in vitro CTL responsiveness, which contrasted with profound alterations of the epithelial cell network and severely reduced serum thymulin levels. This hormonal dysfunction was shown to be directly associated with a reduction in the number of thymulin-containing cells. Moreover, no anti-thymulin auto-antibodies could be detected. The results are discussed with respect to the role of thymic hormonal dysfunction in the modulation of F1 CTL responses observed during the course of a GvH reaction, and the additional analogy of this GvH model with human immunodeficiency.

APA, Harvard, Vancouver, ISO, and other styles

40

Lang, P., M. W. Miller, and G. M. Shearer. "Failure of bone marrow cells to reconstitute T cell immunity in graft-vs-host mice." Journal of Immunology 134, no. 4 (1985): 2050–52. http://dx.doi.org/10.4049/jimmunol.134.4.2050.

Full text

Abstract:

Abstract A chronic GVH reaction (detected by T cell immune deficiency) was induced in unirradiated, adult (C57BL/10 X B10.A)F1 mice by injecting them i.v. with 3 X 10(7) B10.A parental spleen cells. Thirty-four days later, attempts were made to reconstitute the GVH immune-deficient mice by whole-body irradiation and repopulation with bone marrow cells from normal syngeneic F1 mice. The reconstituted mice were tested for CTL responses 147 and 272 days after repopulation with normal F1 bone marrow. These GVH/chimera mice remained immunoincompetent for at least 272 days for CTL responses to hapten-self and H-2 allogeneic antigens.

APA, Harvard, Vancouver, ISO, and other styles

41

Morris, S. C., R. L. Cheek, P. L. Cohen, and R. A. Eisenberg. "Allotype-specific immunoregulation of autoantibody production by host B cells in chronic graft-versus host disease." Journal of Immunology 144, no. 3 (1990): 916–22. http://dx.doi.org/10.4049/jimmunol.144.3.916.

Full text

Abstract:

Abstract A chronic graft-vs-host (GVH) reaction induced in nonautoimmune mice by the transfer of Ia-incompatible spleen cells results in a syndrome that closely resembles SLE in the spectrum of autoantibodies and immunopathology. We have utilized Ia- and Igh-congenic strains to study the immunoregulation of autoantibody-producing B cells in this model. We have found that the autoantibodies are produced almost entirely by the host B cells. The transferred donor B cells contributed neither to the autoimmune response nor to the total serum Ig, with rare exceptions. The donor cell population did, however, exert an Igh allotype-specific immunoregulatory effect on the host B cells. For example, in allotype-heterozygous recipients, the autoantibodies were preferentially made by those host cells that expressed the donor allotype, whereas those host B cells that expressed nondonor allotype were relatively suppressed. In allotype-homozygous recipients, the donor cells frequently suppressed the host IgG2a allotype completely. This suppression sometimes prevented the IgG antichromatin response, although in other cases the response occurred with the use of a different isotype. In a final set of experiments, a chronic GVH reaction was induced in which both the donors and the recipients were Igh allotype heterozygous and yet differed at Ia. In this case, no donor influence on allotype should be expected; yet the IgG2a autoantibodies were clearly skewed toward the b allotype. These results show that host B cells play a unique role in the GVH autoimmune syndrome. In addition, they are immunoregulated in allotype-specific manners, some of which presumably involve interaction with donor T cells.

APA, Harvard, Vancouver, ISO, and other styles

42

Ildstad, S. T., S. M. Wren, J. A. Bluestone, S. A. Barbieri, D. Stephany, and D. H. Sachs. "Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10)." Journal of Immunology 136, no. 1 (1986): 28–33. http://dx.doi.org/10.4049/jimmunol.136.1.28.

Full text

Abstract:

Abstract Reconstitution of lethally irradiated mice with a mixture of T cell-depleted syngeneic plus T cell-depleted allogeneic bone marrow (B10 + B10.D2----B10) leads to the induction of mixed lymphopoietic chimerism, excellent survivals, specific in vivo transplantation tolerance to subsequent donor strain skin grafts, and specific in vitro unresponsiveness to allogeneic donor lymphoid elements as assessed by mixed lymphocyte reaction (MLR) proliferative and cell-mediated lympholysis (CML) cytotoxicity assays. When B10 recipient mice received mixed marrow inocula in which the syngeneic component had not been T cell depleted, whether or not the allogeneic donor marrow was treated, they repopulated exclusively with host-type cells, promptly rejected donor-type skin allografts, and were reactive in vitro to the allogeneic donor by CML and MLR assays. In contrast, T cell depletion of the syngeneic component of the mixed marrow inocula resulted in specific acceptance of allogeneic donor strain skin grafts, whether or not the allogeneic bone marrow was T cell depleted. Such animals were specifically unreactive to allogeneic donor lymphoid elements in vitro by CML and MLR, but were reactive to third party. When both the syngeneic and allogeneic marrow were T cell depleted, variable percentages of host- and donor-type lymphoid elements were detected in the mixed reconstituted host. When only the syngeneic bone marrow was T cell depleted, animals repopulated exclusively with donor-type cells. Although these animals had detectable in vitro anti-host (B10) reactivity by CML and MLR and reconstituted as fully allogeneic chimeras, they exhibited excellent survival and had no in vivo evidence for graft-vs-host disease. In addition, experiments in which untreated donor spleen cells were added to the inocula in this last group suggest that the presence of T cell-depleted syngeneic bone marrow cells diminishes graft-vs-host disease and the mortality from it. This system may be helpful as a model for the study of alloresistance and for the identification of syngeneic cell phenotypes, which when present prevent engraftment of allogeneic marrow.

APA, Harvard, Vancouver, ISO, and other styles

43

Mann, Steven, and Matthew Kuhar. "284 Hypertrophic Variant of Cutaneous Graft Vs Host Disease Clinically Mimicking a Drug Reaction: A Case Report." American Journal of Clinical Pathology 149, suppl_1 (2018): S120—S121. http://dx.doi.org/10.1093/ajcp/aqx123.283.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Kosmatopoulos, K., D. S. Algara, and S. Orbach-Arbouys. "Anti-receptor anti-MHC cytotoxic T lymphocytes: their role in the resistance to graft vs host reaction." Journal of Immunology 138, no. 4 (1987): 1038–41. http://dx.doi.org/10.4049/jimmunol.138.4.1038.

Full text

Abstract:

Abstract Specific resistance to local graft vs host reaction (GvHR) observed in F1 hybrids pretreated s.c., i.p., or i.v. with parent strain spleen cells has been explained as being due to cytotoxic cells induced in these pretreated F1 hybrids and directed against cells bearing receptors that recognize the major histocompatibility complex (MHC) alloantigens of the opposite parent strain (anti-receptor anti-MHC cytotoxic T lymphocytes; CTL). These anti-receptor anti-MHC CTL, however, have never been detected directly in popliteal lymph nodes (PLN), which develop a specific resistance to GvHR. In this paper, we describe the detection of anti-receptor anti-D2 cytotoxic activity in both right and left PLN of B6D2F1 hybrids injected s.c. in the right footpad only with B6 spleen cells. This cytotoxic activity appears 4 days after the injection of B6 cells and diminishes by day 7. It is mediated by a Thy-1+, L3T4-, Lyt-2+ cell of B6D2F1 origin and induced by the injection of either Thy-1+L3T4+Lyt-2- or Thy-1+L3T4-Lyt-2+ B6 spleen cells. The anti-receptor anti-D2 CTL activity is not observed in PLN of B6D2F1 hybrids pretreated i.p. or i.v. with B6 spleen cells. Our results demonstrate that anti-receptor anti-MHC CTL can fully explain the specific resistance to GvHR induced by the s.c. pretreatment of F1 hybrids with parent strain spleen cells. Their role, however, in the resistance to GvHR observed in F1 hybrids i.v. or i.p. pretreated is far from being entirely proven.

APA, Harvard, Vancouver, ISO, and other styles

45

Vandenabeele, P., D. Abramowicz, D. Berus, et al. "Increased IL-6 production and IL-6-mediated Ig secretion in murine host-vs-graft disease." Journal of Immunology 150, no. 9 (1993): 4179–87. http://dx.doi.org/10.4049/jimmunol.150.9.4179.

Full text

Abstract:

Abstract BALB/c mice neonatally injected with semiallogenic (A/J x BALB/c)F1 splenocytes develop a host-vs-graft (HVG) reaction between host T cells and donor B cells, resulting in hypergammaglobulinemia, splenomegaly, and increased serum levels of various autoantibodies. This syndrome is associated with a polyclonal activation of the donor-derived B cells. High serum levels of IL-6 were found in 4-wk-old mice undergoing HVG disease (mean +/- SEM, 132 +/- 93 as compared with 12 +/- 2 in control mice, p &lt; 0.05). Also supernatants of spleen cell cultures from HVG mice contained increased levels of IL-6. In situ hybridization and cell depletion experiments demonstrated that host macrophages were responsible for this pathologic IL-6 secretion. The spontaneous in vitro production of autoreactive antibodies by donor B cells from HVG mice was further enhanced by adding human rIL-6, whereas addition of human rIL-1 beta, human rIL-2, murine rIL-4, murine rIL-5, or combinations of these cytokines had no effect. Finally, addition of blocking anti-IL-6 and anti-IL-6 receptor mAb markedly reduced hyper IgG1 production in cultures of spleen cells from HVG mice. These data suggest that an increased production of IL-6 by persistently stimulated host macrophages is involved in the activation of donor B cells leading to HVG disease.

APA, Harvard, Vancouver, ISO, and other styles

46

Sado, T., H. Kamisaku, and E. Kubo. "Strain difference in the radiosensitivity of immunocompetent cells and its influence on the residual host-vs-graft reaction in lethally irradiated mice grafted with semiallogeneic bone marrow." Journal of Immunology 134, no. 2 (1985): 704–10. http://dx.doi.org/10.4049/jimmunol.134.2.704.

Full text

Abstract:

Abstract A striking difference in radiosensitivity was noted between C3H/He (H-2k) and C57BL/6J (H-2b) strain mice when assessed by primary anti-SRBC PFC response of intact animals and primary cell-mediated lympholysis (CML) response of spleen cells to allogeneic cells in vitro, the C3H strain being more radioresistant. On the other hand, when C3H and B6 mice were exposed to 6.62 to 10.40 grays (Gy) of x-rays and then were transplanted with 2 X 10(6) bone marrow cells from B6C3F1 (H-2b/k) donor mice within 3 hr or at 24 hr after radiation exposure, the early mortality caused by residual host-vs-graft (HVG) reaction was much higher when C3H mice were used as recipients. Furthermore, the proportion of surviving animals manifesting host-type lymphohemopoiesis, i.e., host-type revertants, was much higher in B6C3F1 to C3H than in B6C3F1 to B6 combination. Spleen cells from such host-type revertants manifested strong anti-donor reactivity when assessed by mixed lymphocyte reaction (MLR) and/or CML in vitro. Increase of radiation doses to the recipients to 10.40 Gy resulted in 100% survival and 100% donor-type lymphohemopoiesis in both groups of chimeras. These results indicate strongly that a genetic difference in radiosensitivity of immune system of the recipients can greatly influence the magnitude of residual HVG reactions observed in hybrid to parental strain bone marrow transplantation in mice.

APA, Harvard, Vancouver, ISO, and other styles

47

Ma, Hui-Hui, Jing Fu, Suzanne Lentzsch, and Markus Y. Mapara. "Role of MMP-13 in Graft-Versus-Host Disease." Blood 134, Supplement_1 (2019): 1928. http://dx.doi.org/10.1182/blood-2019-127703.

Full text

Abstract:

Matrix metalloproteinases (MMPs) have been initially recognized for their role in degradation of extracellular matrix (ECM) and collagen remodeling. However, MMPs have been shown to play a crucial role in inflammation, tumor cell invasion, adaptive and innate immunity. Acute and chronic Graft versus Host Disease (GVHD) are characterized by distinctive histopathological features involving tissue infiltration with donor cells, tissue damage and remodeling. We therefore hypothesized that GVHD-associated organ damage may involve MMPs. We have now identified a novel immunomodulatory function for MMP-13 (alternatively called collagenase-3)and have uncovered a previously unknown role of MMP-13 in regulating GVHD.To address the function of MMP-13 in GVHD we first assesed the effect of MMP-13 on alloresponses in vitro. Using fully Major Histocompatibility Complex (MHC)-mismatched standard mixed lymphocyte reaction we demonstated that antigen presentig cells (APC) from B6.MMP-13-/-(H2b) mice led to signifcantly enhanced antigen-driven activation and proliferation of Carboxyfluorescein succinimidyl ester (CFSE)-labeled Balb/c responder splenocytes. Thus, MMP-13 deficiency in either splenocytes or bone marrow-derived dendritic cells used as stimulators resulted in enhanced proliferation, activation and IFN-gproduction in the allo-reactive lymphocyte responders. Similarly, exogenous MMP13 reduced proliferation of responder T cells as determined tested by CFSEdilution (CFSEloof CD4+T cells from 62.3% decreased to 40.6%, CFSEloof CD8+T cells from 74.1% down to 47.9%). We next assessed the impact of MMP-13 in vivousing fully MHC-mismatched rodent acute GVHD models. To study the role of host-derived MMP-13 we induced GVHD in B6.MMP-13-/-or B6.WT recipient mice following lethal TBI (1075 rad) using splenic T cells from Balb/cdonors. We observed signifcantly accelerated GVHD-related mortality (Median Survival Time 7 vs. 47 days post-transplant, p<0.05) in MMP-13-deficient recipients. Most importantly, donor T cells expanded more vigorously in the secondary lymphoid organs (Spleen and mesenteric lymphnoodes) of MMP13-/-compared to wildtype recipient mice (e.g. spleen: absolute donor CD4+Tcells 1.5x104± 7.3 x 103 (WT) vs. 5.83 x104±1.65 x104[MMP-13-/-] and CD8+5.5 x104± 3.8 x104(WT) vs 3.4 x105±1.4 x105[MMP-13-/-], p<0.01). Enhanced donor lymphocyte expansion was further confirmed by bioluminescence imaging. To further delineate the underlying mechanisms, we analyzed the effects of MMP-13deficiency and exogenous MMP-13 on maturation of mouse bone marrow derived-dendritic cells (BMDC) and macrophages in vitro. We noted decreased expression of inhibitory molecules PD-L1 and PD-1H on GM-CSF/LPS cultured BMDC. Similarly, bone marrow-derived MMP-13-/-macrophages also showed reduced PD-L1 and PD-1H expression upon LPS stimulation when compared to their WT counterparts. In summary we posit that recipient myeloid cell-derived MMP-13 mitigates GVHD and limits donor T cell expansion. Further studies are warranted to determine how MMP-13 suppresses expansion of donor T cells and impacts Graft-versus-Leukemia responses. Disclosures Lentzsch: Caelum Biosciences: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Bayer: Consultancy; Janssen: Consultancy; Takeda: Consultancy; Abbvie: Consultancy; Clinical Care Options: Speakers Bureau; Sanofi: Consultancy, Research Funding; Multiple Myeloma Research Foundation: Honoraria; International Myeloma Foundation: Honoraria; Karyopharm: Research Funding; Columbia University: Patents & Royalties: 11-1F4mAb as anti-amyloid strategy; Proclara: Consultancy; BMS: Consultancy.

APA, Harvard, Vancouver, ISO, and other styles

48

Rolink, A. G., T. Radaszkiewicz, and F. Melchers. "The autoantigen-binding B cell repertoires of normal and of chronically graft-versus-host-diseased mice." Journal of Experimental Medicine 165, no. 6 (1987): 1675–87. http://dx.doi.org/10.1084/jem.165.6.1675.

Full text

Abstract:

A quantitative analysis of the frequencies of autoantibody-producing B cells in GVHD and in normal mice has been undertaken by generating collections of hybridomas of activated B cells. These hybridomas secreted sufficient quantities of Ig to allow binding analyses on a panel of autoantigens. B cells have been activated in a variety of ways. In vivo they were activated by injection of alloreactive T cells of one parent, leading to GVHD by a foreign antigen, sheep erythrocytes, in a secondary response, or by the polyclonal activator LPS. B cells from an experimentally unstimulated animal were used for an analysis of the normal background. In vitro B cells were activated by alloreactive T cells or by LPS. The frequencies of hybridomas and, therefore, of activated B cells producing autoantibodies to DNA or to kidney were not significantly different in mice activated by a graft-vs.-host T cell response as compared with B cell populations activated by any of the other procedures. They were found to compose 7.1-17.1% of the total repertoire of activated B cells. Moreover, the frequencies of autoantibody-producing activated B cells does not change with time after induction of the graft-vs.-host reaction. The pattern and frequencies of autoantigen-binding specificities to cytoskeleton, smooth muscle, nuclei, mitochondria, and DNA were not found to be different in any of the groups of hybridomas. The single notable exception, found in GVHD mice, were hybridomas producing autoantibodies to kidney proximal tubular brush border. These results allow the conclusion that autoantigen-binding B cells exist in an activated state in GVHD mice, as well as in mice activated by a foreign antigen or by a polyclonal activator, in B cell populations activated in vitro either by alloreactive T cells or by a polyclonal activator, and even in the background of experimentally unstimulated animals. T cell-mediated graft-vs.-host activation, in large part, does not lead to a selective expansion of autoantigen-binding B cells. The main difference between the graft-vs.-host-activated B cell repertoire and all others is that approximately 90% of teh autoantibodies were of the IgG class, whereas al autoantibodies found in the other groups were IgM.

APA, Harvard, Vancouver, ISO, and other styles

49

Truitt, Robert L., Bryon D. Johnson, Nancy Eisenberg, and Cathleen McCabe. "USE OF T-CELL SPECIFIC MONOCLONAL ANTIBODIES TO MANIPULATE GRAFT-VS-HOST (GVH) and GRAFT-VS-LEUKEMIA (GVL) REACTIONS AFTER BMT IN MICE." Journal of Immunotherapy 14, no. 4 (1993): 369. http://dx.doi.org/10.1097/00002371-199311000-00065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kawakami, Tamihiro, Madoka Takimoto, and Yoshinao Soma. "Late appearance of an acute graft-vs.-host disease reaction subsequent to a graft-vs.-tumor effect induced by bone marrow transplantation in a refractory ovarian carcinoma patient." International Journal of Dermatology 49, no. 3 (2010): 308–10. http://dx.doi.org/10.1111/j.1365-4632.2009.04261.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Host vs Graft Reaction'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles